Literature DB >> 9555606

Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".

J Gheuens, J A Grebb.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9555606     DOI: 10.1097/00004714-199804000-00015

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  6 in total

1.  Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.

Authors:  S Almond; O O'Donnell
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

Review 2.  Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 3.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

4.  Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

Authors:  E T Edgell; S W Andersen; B M Johnstone; B Dulisse; D Revicki; A Breier
Journal:  Pharmacoeconomics       Date:  2000-12       Impact factor: 4.981

Review 5.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  [Differential indications for atypical neuroleptics: Amisulprid, Clozapin, Olanzapin, Quetiapin und Risperidon. Results of a pilot study of prescription habits in psychiatric clinical usage in the BRD].

Authors:  W Günther; G Laux; W Trapp; N Müller; N Mitznegg; H Schulze-Mönking; R Steinberg; M Wolfersdorf
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.